This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Flamel Technologies Announces Results Of Annual Meeting

Stocks in this article: FLML

Flamel Technologies S.A. (NASDAQ: FLML) today announced the results of its annual ordinary and extraordinary meeting held on June 24, 2011, chaired by Mr. Elie Vannier. The election of all members of the Board of Directors of the Company proposed for renewal for a further one-year term was approved by holders of 93% of the Company’s shares. Each additional resolution proposed favorably by management at the meeting was approved overwhelmingly.

Mr. Elie Vannier will continue to serve as the Company’s non-Executive Chairman. Also re-elected to the Company’s Board of Directors were: Mr. Lodewijk J.R. de Vink, former Chairman and Chief Executive Officer of Warner Lambert; Dr. Francis J.T. Fildes, former Senior Vice President, Head of Global Development for AstraZeneca; Mr. John Vogelstein, former President of Warburg Pincus; and Mr. Stephen H. Willard, Flamel’s Chief Executive Officer. In addition, shareholders voted in favor of the three new board members that were nominated. The three new members of the board are: Dr. Catherine Bréchignac, Permanent Secretary of the French Academy of Sciences and former Chairwoman of the National Center for Scientific Research (CNRS); Mr. Guillaume Cerutti, the Chairman and CEO of Sotheby’s France; and the Honorable Craig Stapleton, former United States Ambassador to France.

“We are pleased to have the continued support of Flamel’s shareholders,” said Mr. Elie Vannier, non-Executive Chairman of Flamel. “We now are working with nine of the top twenty-five pharmaceutical companies in the world on projects that involve both novel and already-marketed molecules, including the beta interferon project that we are developing with Merck Serono. Both of the Company’s drug delivery technology platforms maintain considerable comparative advantage in their respective areas and have been the subject of numerous patent applications in the past year. Additionally, the company has pursued relationships using these platforms to develop first in class product opportunities with development stage biotechnology and specialty pharmaceutical companies as an additional component to our diversified partnering strategy. These opportunities may result in increased economic participation in the relevant molecules being developed. We continue to be well-positioned to leverage the advantages that both platforms bring to our partners with respect to safety and efficacy, as well as greater convenience for patients and their caregivers. As a result, we believe in the coming year we will achieve important milestones with our lead projects, with the additional benefit of providing all of our shareholders with increased visibility to the work that the Company is conducting with our partners.”

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs